Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	23.30B -13.1%
Revenue (ttm)	4.56B +17.1%
Net Income	-328.92M
EPS	-0.60
Shares Out	575.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	5.69 (14.05%)
Ex-Dividend Date	Jul 31, 2025

Volume	172,444
Open	40.48
Previous Close	40.48
Day's Range	39.54 - 40.86
52-Week Range	15.01 - 51.70
Beta	-0.19
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C. The company also engages in the import, export, wholesale, retail, and distribution of pharmaceutical products, intermediates, and active pharmaceutical ingredients; product quality inspection; research and development of biosimilar drugs and new biol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 6,299
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error